
FDA Initiatives and Programs to Support Development of Treatments for Rare Diseases in 2026
Discover FDA programs in 2026 that foster rare disease drug development, offering guidance, funding, and regulatory support for innovators.
Home > Education Hub > Articles

Discover FDA programs in 2026 that foster rare disease drug development, offering guidance, funding, and regulatory support for innovators.

Discover how a strategically planned clinical evidence generation strategy can support global device approval, maximize evidence value, and prepare for international expansion.

Explore how patient-reported outcome complexity, subtype-stratified trials, and AI are shaping product development in myasthenia gravis.

Learn how pharma and medtech convergence is reshaping drug delivery system partner selection, from combination products and regulatory readiness to integrated execution.

Discover how stakeholder engagement helps rare disease manufacturers prepare for JCA and how to apply stakeholder management best practices in the JCA context.

Learn where patient involvement fits within JSC and JCA under EU HTA Regulation and how to prepare your engagement strategy.